Gilead Sciences stock heads into Denver meeting with liver data

Gilead Sciences will present new clinical and real-world evidence on rare liver diseases at The Liver Meeting 2026 in Denver from November 5 to 9. The company announced the program on October 22, with the American Association for the Study of Liver Diseases conference serving as the next scheduled event for its liver portfolio.

Gilead Sciences stock traded at 150.78 euros on Lang & Schwarz at 11:09 CET on Monday, November 2, 2.29 percent below the Xetra close of Friday, October 30. Investors can follow the real-time quote of Gilead Sciences stock.

Late-breaking PBC evidence leads program

The company said its scientific program includes 21 accepted abstracts. The main primary biliary cholangitis focus is a late-breaking Phase 3 presentation from the IDEAL study, which evaluates seladelpar, marketed as Livdelzi, in adults with lower levels of alkaline phosphatase elevation who were taking or unable to tolerate ursodeoxycholic acid.

The IDEAL presentation is scheduled for November 8 and will examine composite alkaline phosphatase normalization. Gilead describes the marker as an important measure of disease activity, while the company is also set to present longer-term safety and efficacy evidence for seladelpar through five years of treatment. Another late-breaking presentation will address fatigue, a symptom that can weigh heavily on quality of life for people with primary biliary cholangitis.

The planned evidence extends beyond trial efficacy. Additional analyses will examine factors affecting eligibility for and escalation to second-line treatment, treatment adherence, health-related quality of life and healthcare use. Those topics could help investors assess whether Livdelzi's commercial opportunity depends not only on clinical activity but also on diagnosis, treatment persistence and broader adoption in routine care.

Hepatitis delta evidence broadens focus

Gilead will also present long-term and real-world evidence for Hepcludex, its treatment for chronic hepatitis delta virus infection. The program includes a 96-week analysis of combined virologic and biochemical response and a 48-week analysis of clinically significant portal hypertension in people receiving treatment.

Presentations on November 7 will address treatment response, disease progression, non-invasive fibrosis testing and the effect of therapy on portal hypertension. A separate November 8 analysis will examine hepatitis delta testing rates among people with chronic hepatitis B. Gilead said the findings are intended to highlight the need for earlier detection and stronger long-term disease management.

Management's message is that treatment decisions should be informed by more than short-term biochemical markers. Swati Tole, Gilead's senior vice president for clinical development in inflammation, said the company intends to present evidence on response durability, symptoms and the practical realities of long-term care. The statements describe planned presentations rather than results already released from the Denver meeting.

Next catalyst comes in Denver

The Liver Meeting is the next clearly scheduled catalyst for the liver portfolio. The November 5 to 9 timetable places early poster sessions on long-term seladelpar and hepatitis delta evidence before the late-breaking PBC presentation on November 8.

The S&P 500 remains the relevant market backdrop for this US-listed company; current market reports provide the broader index context.

For investors, the meeting should clarify how Gilead is positioning Livdelzi and Hepcludex within long-term care pathways for rare liver diseases. More news and analyses on Gilead Sciences stock will track subsequent clinical and market developments.